Alerta

一种负载核苷类似物的递送系统及其制备方法和应用

Resumen de: CN121265559A

本发明提供了一种负载核苷类似物的递送系统及其制备方法和应用，涉及医药技术领域。本发明中通过膜工程改造首次采用血小板膜与MSC细胞外泌体杂化获得的包裹材料负载吉西他滨，获得了高包封率、高载药量的吉西他滨递送系统，并且该系统具有优异的稳定性；该负载吉西他滨的血小板膜药物递送系统能够有效提高吉西他滨的胰腺癌治疗效果，为胰腺癌治疗提供了一种新的功能性药物形式。

一种用于局部给药的脂质纳米颗粒、其制备方法及其在制备抗疤痕药物上的应用

Resumen de: CN121265557A

本发明属于生物医药领域，具体涉及一种用于局部给药的脂质纳米颗粒、其制备方法及其在制备抗疤痕药物上的应用。本发明的脂质纳米颗粒，包含脂质载体以及由所述脂质载体所包裹的核酸，所述脂质载体包含以下成分：可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物；所述可电离脂质、永久性阳离子脂质、聚乙二醇化脂质、辅助磷脂和甾醇类化合物的摩尔比为：25‑45：5‑25：1‑2：5‑15：35‑40。本发明针对现有技术存在的脂质纳米颗粒给药单一性的问题，将脂质纳米颗粒通过比例调控，设计成外用涂抹局部给药，提高靶向性、可给药浓度。避免全身血液循环，降低毒副作用、脱靶性。从而达到“增效”与“减毒”的双重目的。

一种靶向性的药物递送载体及其制备方法

Resumen de: CN120242044A

The invention belongs to the technical field of biological medicine, and relates to a targeting drug delivery carrier and a preparation method thereof. The invention provides a targeting drug delivery carrier. The targeting drug delivery carrier comprises a drug carrier and targeting polypeptide, the drug carrier is a virus carrier, and the nucleotide of the targeting polypeptide is operably connected with the nucleotide of the capsid protein of the virus carrier; or the drug carrier is a non-viral carrier, the targeting polypeptide is connected with the non-viral carrier in a surface modification mode, and the amino acid sequence of the targeting polypeptide is shown as any one of SEQ ID NO: 8-12 and SEQ ID NO: 14. The efficient drug delivery carrier is designed and prepared by utilizing targeting polypeptide for specifically recognizing biomolecules, cells, tissues or organs.

两亲性嵌段聚合物、载药纳米颗粒粉末、载药水凝胶及制备方法和应用

Resumen de: CN121270779A

本发明公开了两亲性嵌段聚合物、载药纳米颗粒粉末、载药水凝胶及制备方法和应用，涉及骨损伤修复药物技术领域。两亲性嵌段聚合物的制备方法为：4‑二甲氨基苯酚与2‑溴异丁烯酰溴混合反应，得到引发剂P1；N‑叔丁羰基乙醇胺与甲基丙烯酰氯混合反应，得到单体Boc‑AEMA；1‑甲基‑2‑羟甲基咪唑与甲基丙烯酰氯混合反应，得到单体MPID；引发剂P1与单体Boc‑AEMA、单体MPID混合反应，得到聚合物BMP1；聚合物BMP1与三氟乙酸混合反应，得到两亲性嵌段聚合物BMP2。本发明通过设计含阳离子咪唑基团MPID与疏水脱保护胺基Boc‑AEMA的两亲性嵌段聚合物BMP2，突破传统凝胶需添加化学交联剂的局限，通过静电自交联触发原位凝胶化，规避外源交联剂导致的细胞毒性，且凝胶强度可通过聚合物浓度精准调控。

一种靶向肝实质细胞的核酸递送载体及其应用

Resumen de: CN121265551A

本发明涉及局部递送药物的材料及其应用。具体提供一种纳米颗粒组合物，所述纳米颗粒组合物包括阳离子脂质、PEG脂质和结构脂质；其中，PEG脂质的脂质组分为1.0‑5.5摩尔％，或上述任意两个数值之间的范围。本发明纳米颗粒组合物仅在施用部位递送。

一种可屏蔽NETs的神经营养因子纳米递送系统及其应用

Resumen de: CN121265756A

本发明涉及一种可屏蔽NETs的神经营养因子纳米递送系统及其应用，属于生物医药技术领域。本发明通过ATP对荷正电的BDNF进行可逆修饰得到荷负电的A‑BDNF；通过LPS处理小胶质细胞得到高表达聚唾液酸的小胶质细胞膜，使用PBM包被A‑BDNF得到A‑BDNF@PBM NPs。本发明的A‑BDNF@PBM NPs可有效富集于受损脊髓部位，并通过PBM表面高表达的聚唾液酸与NETs结合，触发PBM脱落，使位于PBM胞质小叶的PS暴露在NETs表面，PS充当“吃我”信号，使吞噬细胞通过胞葬作用清除NETs，引发神经保护性免疫反应。同时，释放的A‑BDNF在微酸性环境下恢复为BDNF，促进神经再生。

ポリサルコシンを含むＲＮＡ粒子

Resumen de: US2025367320A1

The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.

ＲＳＶ感染によって引き起こされる疾患又は障害を予防する方法

Resumen de: US2022133875A1

The present invention is generally related to modified or mutated respiratory syncytial virus (RSV) fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. Specifically, the disclosure provides a method of maternal immunization comprising administering a composition comprising an RSV F protein and an adjuvant to a pregnant woman carrying a gestational infant, wherein the method induces an immune response against at least one symptom associated with RSV lower respiratory tract infection (LRTI) in the infant following birth.

ＣＴＭ標的指向化による敗血症性胆汁うっ滞の治療のためのＰＫＣ阻害剤

Resumen de: US2025268913A1

The invention relates to inhibitors of the PKC signaling pathway for use in the treatment of septic cholestasis, wherein the inhibitors are targeted into the liver by a selective nanostructured delivery system, wherein the selective nanostructured delivery system comprises at least one carbohydrate targeting moiety and at least one polymer and/or at least one lipid and/or at least one virus-like particle.

一种脂质纳米颗粒的制备及其在膀胱灌注药物中的应用

Resumen de: CN121265556A

本发明提供了一种脂质纳米颗粒的制备及其在膀胱灌注药物中的应用，属于生物医药技术领域。本发明脂质纳米颗粒由离子型脂质、胆固醇、两亲性脂质和DOPE‑LA组成；所述离子型脂质为阳离子脂质或可电离脂质，该脂质纳米颗粒（LANP）表面具有二硫戊环结构，能够与细胞表面的巯基发生巯基‑二巯基交换反应，将LANP以化学键的形式黏附在膀胱内壁的黏膜上，以抵抗尿液外排导致的药物有效浓度降低。

用于治疗免疫应答失调的基于微小RNA的颗粒

Resumen de: AU2024207086A1

A miRNA-mimic based therapeutic particle is disclosed herein. The particles comprise a synthetic miRNA or mimic of miR-187-3p encapsulated in a lipid nanoparticle (LNP) carrier or synthetic miR-193b-5p inhibitor encapsulated in a lipid carrier or their combination encapsulated in a lipid carrier. The lipid nanoparticle carrier is made up of at least four (4) types of lipids, in which the four (4) types of lipids include a) an ionizable cationic lipid selected to be positively charged in a formulation buffer (pH 4), which binds and protects the negatively charged miRNA, and facilitates endosomal escape, and is neutral in a storage buffer, b) a sterol in the structure of the lipid nanoparticle (LNP)., c) a structural helper lipid selected to contribute to lipid nanoparticle stability and/or enhances endosomal release, and d) a PEGylated-lipid selected such that it stabilizes the therapeutic particle and protects it from opsonization.

叶酸修饰的NK细胞来源的外泌体包载溶瘤呼肠孤病毒复合物及其制备方法和应用

Resumen de: CN121265553A

本发明公开了叶酸修饰的NK细胞来源的外泌体包载溶瘤呼肠孤病毒复合物及其制备方法和应用。所述复合物中叶酸与NKexo磷脂双分子层通过自组装插入的方式修饰NKexo；所述复合物中通过挤压法将Reo装载到NKexo中。所述方法包括步骤：提取NKexo，叶酸修饰NKexo，和叶酸修饰的NKexo包载Reo。本发明的叶酸修饰的NKexo包载Reo即能依靠NKexo自身的抗肿瘤特性能成为较好的运送载体，又能够通过叶酸与肿瘤中高表达的叶酸受体结合，从而保护并递送更多的Reo到达肿瘤部位，协同联合靶向治疗癌症。

一种富含大蒜素的植物囊泡及其制备方法和应用

Resumen de: CN121265558A

本发明提供一种富含大蒜素的植物囊泡及其制备方法和应用，在制备大蒜汁液和连续离心除杂后，采用PEG800富集大蒜素，依次从大蒜中粗提小纳米囊泡，较大的微囊泡，大蒜素聚体和提取亲脂成分，再经过薄膜蒸发成薄膜和水化形成重构囊泡，使得大蒜素能够稳定而丰富地包裹在重组囊泡中，形成ASL‑EVLPs，能够有效包载高含量大蒜素，显著提高大蒜素的稳定性并降低其刺激性。采用本发明的方法制备的富含大蒜素的植物囊泡，采用以药制药的方式，延缓细菌耐药和有效抗感染，可以实现广谱抗菌并延缓细菌耐药，对部分革兰氏阳性菌、阴性菌及真菌均有抑制作用，可用于制备与抗菌有关的药物中。

一种脂质纳米颗粒冻干制剂的制备方法

Resumen de: CN120241626A

According to the preparation method of the LNP freeze-dried preparation, the particle size difference before and after LNP freeze-drying can be reduced and the product quality can be improved by adding salt into an LNP solution, adjusting the pH value or carrying out curing treatment and the like.

グルカゴン様ペプチド－１受容体アゴニストを含む新規医薬組成物

Resumen de: AU2023392764A1

There is provided a pharmaceutical formulation that is useful in the treatment of metabolic disorders or conditions, comprising a plurality of particles suspended in a carrier system, which particles: (a) have a weight-, number-, or volume-based mean diameter that is between amount 10 nm and about 700 µm; and (b) comprise solid cores comprising at least one glucagon-like peptide-1 receptor agonist, or a pharmaceutically-acceptable salt thereof, coated, at least in part, by a coating of inorganic material comprising mixture of: (i) zinc oxide; and (ii) one or more other metal and/or metalloid oxides, wherein the atomic ratio ((i):(ii)) is at least about 1:10 and up to and including about 10:1. Said mixed oxide coated particles are preferably synthesized via a gas phase coating technique, such as atomic layer deposition. The formulation may provide for the delayed or sustained release of glucagon-like peptide-1 receptor agonists to treat metabolic disorders or conditions, such as type 2 diabetes and/or obesity without a burst effect. The glucagon-like peptide-1 receptor agonist is preferably liraglutide.

脂質ナノ粒子の凍結乾燥方法及び組成物

Resumen de: CN120390635A

The present invention provides a lyophilized nucleic acid lipid nanoparticle (NALNP) comprising (a) a lipid nanoparticle comprising a nucleic acid, and (b) a lyophilization buffer comprising a sugar, a lyophilization reagent, and a pharmaceutically acceptable diluent; and a preparation method thereof.

インフルエンザおよびＲＳＶに対する免疫原性組成物

Resumen de: TW202430642A

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and/or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

ＳＦＴＳウイルスワクチン

Resumen de: CN120583941A

Provided herein are compositions, systems, kits and methods for immunizing a subject against severe fever with thrombocytopenia syndrome virus (SFTS virus) with a composition i) comprising a plurality of nanoparticles self-assembled by a plurality of fusion proteins comprising a) at least a portion of a ferritin and b) an immunogenic protein, in some embodiments, the fusion protein comprises i) an immunogenic protein comprising at least a portion of an SFTS virus Gn and/or Gc envelope glycoprotein, or ii) a polynucleotide encoding the fusion protein (e.g., an mRNA sequence present in a lipid nanoparticle).

インフルエンザウイルス様粒子をコードするｍＲＮＡ

Resumen de: AU2023394992A1

The present invention relates to a messenger RNA (mRNA)-based immunogenic composition that is capable of inducing a mammalian cell to produce an influenza virus-like particle (VLP). The immunogenic composition comprises one or more mRNAs encoding an influenza virus matrix 1 (M1) protein and one or more influenza virus hemagglutinin (HA) proteins and/or one or more influenza virus neuraminidase (NA) proteins.

阻害性核酸およびその使用方法

Resumen de: CN120603949A

The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of treating cancer using the inhibitory nucleic acids.

聚唾液酸-聚合物缀合物和纳米颗粒

Resumen de: AU2024252577A1

Disclosed herein is a polysialic acid (PSA)-polymer conjugate compound represented by the structural formula (I): or a pharmaceutically acceptable salt thereof, wherein P is a poly(lactide-co-glycolide)-poly(ethylene glycol) copolymer (PLGA-PEG) and p is an integer from 4 to 200, nanoparticles comprising same, and methods of treating ophthalmic diseases using same.

AUTOANTIGEN-SPECIFIC NANOFUSION VACCINE COMPOSITION FOR TREATMENT OF SYSTEMIC SCLEROSIS FOR SIMULTANEOUS IMMUNOMODULATION AND ANTIFIBROSIS

Resumen de: WO2026005488A1

The present invention relates to an autoantigen-specific nanofusion vaccine composition for the treatment of systemic sclerosis, the composition being for simultaneous immunomodulation and antifibrosis. A nanofusion body carrying a vimentin peptide according to the present invention was found to inhibit tissue fibrosis in systemic sclerosis, reduce the amount of autoantibodies in serum, and regulate the expression of immune-regulatory cells and pathogenic cells associated with systemic sclerosis. The nanofusion body was also found to inhibit tissue fibrosis and to exhibit enhanced anti-fibrotic effects, when co-administered with a vimentin antibody, in an animal model reflecting the immune status of systemic sclerosis patients. In addition, the nano-vaccine was found to decrease the expression of fibrotic and pathogenic factors in tissues and was also found to improve disease activity not only in vimentin-specific systemic sclerosis but also in infection-associated systemic sclerosis.

COMPOSITIONS AND METHODS FOR DELIVERY BY INHALATION

Resumen de: WO2026006634A1

The present disclosure provides, inter alia, compositions of LNPs that are suitable for nebulization, and associated methods of making and using the same. In certain aspects, the present disclosure provides LNPs, and compositions comprising them, comprising a simple block stabilizer, to form a LNP composition that is suitable for delivery of a nucleic acid therapeutic to a subject by nebulization, where the LNP remains stable post-nebulization. These compositions can be used to treat a variety of diseases and disorders by delivering a wide array of therapeutics, such as nucleic acid therapeutics, including nucleic acids encoding a protein sequence.

METHOD FOR PRODUCING LIPID NANOPARTICLES

Resumen de: WO2026004828A1

The present invention addresses the problem of providing a method for producing lipid nanoparticles, the method making it possible to produce lipid nanoparticles having a narrow particle size distribution. The present invention provides a method for producing lipid nanoparticles, the method comprising a step 1 for preparing a first solution containing an active ingredient, a step 2 for preparing a second solution containing a prescribed lipid and an alcohol, a step 3 for mixing the first solution and the second solution in a flow channel to prepare a lipid nanoparticle dispersion, a step 4 for mixing and diluting the lipid nanoparticle dispersion A with a third solution at a given ratio and thereby preparing a lipid nanoparticle dispersion B, and a step 5 including a pH adjustment step for adjusting the pH of the lipid nanoparticle dispersion B and an alcohol removal step, the interval from step 3 to step 4 being less than 1 minute, and the alcohol content of the lipid nanoparticle dispersion B being 6-30 vol%.

METHOD FOR PRODUCING LIPID NANOPARTICLES

Nº publicación: WO2026004829A1 02/01/2026

Solicitante:

FUJIFILM CORP [JP]
\u5BCC\u58EB\u30D5\u30A4\u30EB\u30E0\u682A\u5F0F\u4F1A\u793E